Peptides for immunotherapeutic agents
A peptide according to the present document comprises at least one peptide unit, where the peptide unit comprises at least one B-cell epitope and at least one Th epitope, and may comprise a suitable number of helper moieties. The peptide unit is a moiety designed to induce only uniformly a predeterm...
Saved in:
| Main Author | |
|---|---|
| Format | Patent |
| Language | Chinese English |
| Published |
01.08.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
| Summary: | A peptide according to the present document comprises at least one peptide unit, where the peptide unit comprises at least one B-cell epitope and at least one Th epitope, and may comprise a suitable number of helper moieties. The peptide unit is a moiety designed to induce only uniformly a predetermined antibody while exhibiting at least a certain level of immunogenicity in the subject. In addition, the peptide units are designed to be relatively short and thus have the characteristics of easy synthesis and low production costs. The peptide has a property suitable for use as an immunotherapeutic agent due to the properties of the peptide unit described above. The invention describes the design principle of the peptide and the peptide unit in detail.
根据本申请文件的肽包含至少一个肽单元，其中所述肽单元包含至少一个B细胞表位和至少一个Th表位，并且可包含适当数量的辅助部分。所述肽单元是被设计为仅均一地诱导预先预定的抗体同时在受试者体内表现出至少一定水平的免疫原性的部分。此外，所述肽单元被设计为相对短，并因此具有易于合成并且具有低生产成本的特点。由于上述肽单元的特性，所述肽具有适合用作免疫治疗剂的性质。本申请文件详细描述了所述肽和肽单元的设计原理。 |
|---|---|
| Bibliography: | Application Number: CN20218064591 |